Automated Insulin Delivery Boosts Glycaemic Control in Type 1 Diabetes: Real-World Australian Study
Australia: A recent multicentre audit conducted in Queensland, Australia, has provided compelling real-world evidence supporting the use of automated insulin delivery (AID) systems in managing type 1 diabetes mellitus (T1DM). The study, published in Diabetes, Obesity and Metabolism, evaluated the impact of AID therapy on glycaemic control in both metropolitan and regional healthcare settings, revealing significant improvements in blood glucose metrics.
The researchers reported, "The meta-analysis of 16 trials found that fully AID improved time-in-range (TIR) by 10% compared to conventional insulin therapy in type 1 diabetes, with greater benefits seen in younger individuals and those with shorter disease duration. However, fully AID was less effective than hybrid systems (−3.05% vs 17.44% TIR improvement)."
The research involved a retrospective analysis of 158 adults with T1DM who were initiated on AID therapy across three sites—Logan (metropolitan), Mackay, and Townsville (regional). AID systems integrate continuous glucose monitoring with automated insulin dosing, aiming to maintain blood glucose levels within a target range. Although clinical trials have shown promise, the study sought to assess how the technology performs in routine care, especially in less urban areas where access to specialized diabetes services may be limited.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.